Optimization  formula  gastroretentive  tablet  of  ranitidine  HCl with floating system

T.N. Saifullah Sulaiman; Achmad Fudholi; A. Kharis Nugroho

doi:10.14499/indonesianjpharm0iss0pp106-114

Optimization formula gastroretentive tablet of ranitidine HCl with floating system

T.N. Saifullah Sulaiman, Achmad Fudholi, A. Kharis Nugroho

Abstract

Ranitidine HCl is an H-2 receptor antagonists for the treatment of peptic gastric secretion with a small bioavailability, so that should be developed in a sustained release dosage form are retained in the stomach. Ranitidine HCl floating tablet was formulation by effervescent system. Simplex lattice design was applied to optimize the formula of ranitidine HCl floating tablet by varying levels of Methocel K15M 100-185 mg, sodium bicarbonate 15-100 mg, and citric acid0-85 mg. The Optimum formula determined by superimposed contour plot from various parameters: flowability of granules, physical properties of tablet and drug release using Design-Expert®program. Based on superimposed contour plot obtained optimum formula for the area in the range of Methocel K15M 100-145 mg, sodium bicarbonate 20-80 mg and citric acid 25-80 mg.

Key words: Ranitidine HCl, Gastroretentive, Simplex lattice design

Full Text:

Untitled

References

Anonim, 2000, Using METHOCEL Cellulose Ethers for Controlled Release of Drugs in Hydrophilic Matrix Systems, The Dow Chemical Company, USA, 8.

Asif, M., Yasir, M, Bhattacharya, A. and Bajpai, M., 2010, Formulation and evaluation of gastroretentive dosage form for fluvastatin sodium, Pharm. Globale (IJCP), 4 (08), 1-4.

Basit, A., Lacey, L., 2001, Colonic metabolism of ranitidin HCl: implications for its delivery and absorption, Int. J. Pharm., 227 (1-2), 157-165.

Bolton, S. and Bon, C., 2004, Pharmaceutical Statistic: Practical and Clinical Applications, 4th Ed., 590-620, Marcel Dekker, Inc., New York.

Cremer K., 1997, Drug delivery: Gastro- remaining dosage forms. Pharm. J.,259, 108-113

Grant S. 1989, Ranitidin HCl: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer and other allied diseases, Drugs, 37, 801-870.

Gothoskar, A. V., 2005, Extended release formulation using hydrophilic matrices, Modified Release Forum, Colorcon, Jakarta, 17th May 2005.

Harwood, R. J., 2006, Hydroxypropyl Cellulose, in Rowe, (Ed), Handbook of Pharmaceutical Excipients,

th ed, Pharmaceutical press, London.

Jaimini, M., Rana, A. C. and Tanwar, Y. S. 2007, Formulation and Evaluation of Famotidine Floating Tablets, Current Drug Delivery, 4, 51-55

Nadigoti, J. and Shayeda, 2009, Review Article: Floating Drug Delivery Systems, Int. J. Pharm. Sci. and Nanotech., 2 (3), 595-604.

McQuaid, K. R., 2010, Alimentary Tract, in McPhee, S. J. and Papadakis, M. A., (Eds), Current Medical Diagnosis and Treatment, 49th Ed., 588-589, McGraw-Hill, USA.

Pithavala Y. K, Heizer W. D, Parr A. F, O’Connor-Semmes R. L, and Brouwer K. L. 1998, Use of the Inteli Site capsule to study ranitidin HCl absorption from various sites within the human intestinal tract. Pharm. Res.15:1869–1875.

Rocca, J.G., Omidian, H. and Shah, K., 2003, Progress in Gastroretentive Drug Delivery Systems,Bussiness Br iefing Phar matech, 152, www.touchbriefings.com, 18 Juni 2009.

Rosa, M., Zia H. and Rhodes, T., 1994, Design and testing in vitro of a bioadhesive and floating drug delivery system for oral application, Int.J.Pharm., 105,65-70.

DOI: http://dx.doi.org/10.14499/indonesianjpharm0iss0pp106-114